Salivary gland infection is one of the most common medical condition across the globe. These infections are mostly caused due to bacteria or viruses. Salivary gland infection affects salivary duct or gland.
Increasing prevalence of various salivary gland infections, changing disease patterns, and environmental changes are major drivers for the market growth. Rising funding for R&D and clinical trials are leading to improved product development is another key factor for market growth. Improved hygiene practices, growing awareness about self-care and advanced diagnosis and treatment options are important driving forces for the market.
In August 2022, free DNA saliva tests were launched in Australia as one of the first preventive DNA screening programs worldwide for cancer and heart disease risk. It is a nationally collaborative project, led by Australia's Monash University.
In September 2021, Thermo Fisher Scientific launched the Thermo Scientific SpeciMAX Stabilized Saliva Collection Kit, which is designed to collect saliva for research safely. Such initiatives also contribute to the growth of the market.
In June 2022, Goodbody Health Inc. launched four saliva tests that can determine a person's risk of getting cancer or heart disease over ten years via looking at genetics. Such launches are expected to propel the growth of this segment in the future.
LordsMed and Singapore-based diagnostics kit manufacturer Sensing Self have entered into an exclusive partnership to launch one of India's first COVID-19 saliva-based rapid antigen test kits in August 2022.
Eurobio Scientific signed an exclusive distribution contract with Orasure in January 2022 regarding OraQuick commercialization, a saliva self-test. This exclusive contract covers French market and its overseas territories.
However, November of 2022 saw Alembic Pharmaceuticals Ltd stating that generic Glycopyrrolate injection was about to be approved by US health regulators, thereby decreasing salivary flow as well as exudation into airways before operation. Also, according to FDA approval, will be given for Abbreviated New Drug Application (ANDA) on Glycopyrrolate Injection such as single-dose vials ranging from 0.2 mg/1mL up to 0.4mg/2 mL (0 .2mg/ml), etc., including another strength like1mg/5 mL(0 .2mg/ml). Besides or instead of oral preparations, the injection may be co-administered when immediate cholinergic receptor response is needed in adults with gastric ulcers.
LordsMed made an exclusive partnership with Sensing Self, a Singapore-based diagnostics kit manufacturer, to launch one of India's first COVID-19 saliva-based rapid antigen test kits in August 2022.
Study objectives of salivary gland infection market:
Intended Audience:
On the basis of diagnosis which comprises of Plain radiography, sialography, high-resolution ultrasonography, Computed tomography (CT), Magnetic Resonance Imaging (MRI), radionuclide scintigraphy, and others. Sialography is further sub-segmented into CT sialography (ultrafast technique), fluoroscopic/conventional sialography (with or without digital subtraction), and MR sialography.
On the basis of treatment, the market has been segmented into medication, surgery, aspiration, home care, and others. Medication is further sub-segmented into antibiotics and others. Antibiotics are further sub-segmented into dicloxacillin, cephalosporins, clindamycin, and others. Surgery includes removal of part of the parotid salivary gland, removal of all of the parotid salivary gland, removal of the submandibular salivary gland, and others. Home remedies include increased water intake, rest, refraining from smoking, massaging the gland with heat, and others.
On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.
Considering the global scenario of the market, Americas holds the largest market share due to various factors such as increasing number of patients with various salivary gland infections and related disorders. European salivary gland infection market is the second largest where the west European countries are dominating the largest market share. Prevalence of various salivary gland infection is rising in Asia Pacific region. Additionally, increasing healthcare spending and rapidly changing healthcare sector, and government initiatives to improve public health are major growth drivers for Asia Pacific salivary gland infection market. Due to low knowledge of disease and treatments, low-income, and limited access to healthcare facilities, Middle East and Africa (ME&A) is likely to have a limited growth in the market.
The report for Global Salivary Gland Infection Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
| Report Attribute/Metric | Details |
| Market Size 2032 | USD 12.39 billion |
| Compound Annual Growth Rate (CAGR) | 9.34% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Growth Factors, Market Competitive Landscape, and Trends |
| Segments Covered | Types Of Plain radiography, sialography by treatment medication, surgery, aspiration |
| Geographies Covered | North America, Asia-Pacific, Europe, and the Rest of the World |
| Countries Covered | The U.S, Canada, France, the U.K., Germany, Italy, Spain, China, Japan, India, South Korea, Australia, and Brazil |
| Key Companies Profiled | AbbVie Inc. (US), Allergan (Republic of Ireland), AstraZeneca (UK), FUJIFILM Holdings Corporation (Japan), General Electric Company (US), GlaxoSmithKline plc. (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc.(US), Siemens Healthcare GmbH (Germany) |
| Key Market Opportunities | ·      Growing Demand for Minimally Invasive Treatments |
| Key Market Dynamics | ·      Increasing Incidence and Prevalence |
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
